Stefan O. Ochiana, Ph.D.

Associate

vCard

Stefan O. Ochiana, Ph.D.

Associate

+1 202 408 4316 +1 202 408 4316
stefan.ochiana@finnegan.com stefan.ochiana@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Stefan's work in

Stefan Ochiana, Ph.D., prosecutes and provides strategic counseling on U.S. and foreign patent portfolios in the chemical and pharmaceutical arts. His experience also includes assisting with Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act, inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO), and disputes in district courts across the country.

Prior to joining Finnegan, Stefan worked as a post-doctoral research scholar at Memorial Sloan Kettering Cancer Center. His work included several projects aimed at the discovery and development of heat shock protein 90 (Hsp90), Hsp70, glucose-regulated protein 94 inhibitors, and the design and synthesis of chemical probes for the biological evaluation of these targets.

Stefan's graduate dissertation research focused on the design, synthesis, and evaluation of human aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing. Stefan has a wide range of technical experience, including the areas of organic and medicinal chemistry, computational chemistry, drug delivery, preclinical drug development, and chemical biology. He has authored or co-authored eighteen journal papers and a book chapter, presented his research at thirteen national and local conferences, and is a co-inventor on many patent applications related to his postdoctoral work.

Et Cetera

American Cancer Society Postdoctoral Fellowship, 2014.
Dissertation Completion Fellowship, Office of the Provost, Fall 2012.
Coauthor. "Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system," Nature Communications, 2021.
Coauthor. "First in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients," Clinical Cancer Research, 2020.
Coauthor. "Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not," Proceedings of the National Academy of Sciences, USA, 2015.
Coauthor. "Structure-Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94," Journal of Medicinal Chemistry, 2015.
Coauthor. "Selective Targeting of the Stress Chaperome as a Therapeutic Strategy," Trends in Pharmacological Sciences, 2014.
Coauthor. "Heat Shock Protein 90 Inhibitors in the Treatment of Cancer: Current Status and Future Directions," Expert Opinion on Investigational Drugs, 2014.
Coauthor. "Designing Drugs Against Hsp90 for Cancer Therapy," The Molecular Chaperones Interaction Networks in Protein Folding and Degradation, Sept. 2, 2014.
Coauthor. "The Human Aurora Kinase Inhibitor Danusertib Is a Lead Compound for Anti-Trypanosomal Drug Discovery Via Target Repurposing," European Journal of Medicinal Chemistry, 2013.

Experience

Represented patent owner in inter partes review (IPR) challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.

IPR2019-00865, PTAB, Judges Cotta, Snedden, Mitchell

Represented Novembal USA, Inc., the declaratory judgment defendant, in this multi-design patent case directed to designs for closures for bottles. This case favorably settled during discovery.

1:19-cv-03944, S.D. Ind., Judge Dinsmore

Represented Salient Systems in litigation against Hawk Technology Systems. Salient Systems’ Complaint alleged breach of contract, breach of covenant of good faith and fair dealing, fraud, tortious interference with business relations, patent invalidity, patent misuse, and violations of the Sherman Act. The Chief Judge ruled in Salient’s favor on Hawk’s dispositive motion against Salient’s Complaint, denying Hawk’s motion in its entirety.

1:20-cv-01558, D. Del., Judge Connolly

Represented Tyler Stonegate Property Owners Association in patent litigation brought by Hawk Technology Systems, resulting in dismissal of the case.

6:20-cv-00572, E.D. Tex., Judge Barker

Represents Castle Retail in patent litigation brought by Hawk Technology Systems. Judge McCalla ruled in Castle Retail’s favor, granting Castle Retail’s Rule 12 motion and invalidating Hawk’s patent claims. The case is currently on appeal before the Federal Circuit.

2:20-cv-02766, W.D. Tenn., Judge McCalla

Represented Defendant Kirkland’s and Intervenor Salient Systems in patent litigation brought by Hawk Technology Systems. The case was dismissed with prejudice.

3:20-cv-00276, N.D. Miss., Judge Mills

News

Announcement

Finnegan Announces 2019 Mentors of the Year Finnegan Announces 2019 Mentors of the Year

December 30, 2019

Professional Activities

American Bar Association
American Chemical Society

Admissions and Education

Admissions

District of Columbia
Massachusetts

U.S. Court of Appeals, Federal Circuit
U.S. Patent and Trademark Office

Education

George Washington University Law School: J.D., with honors, 2021

Northeastern University: Ph.D., Organic Chemistry, 2013

Saint Vincent College: B.S., Biochemistry, 2008

Languages

Romanian

Stefan's Practices

Patent Litigation: Branded Hatch-Waxman (ANDA)
Patent Office Examinations: Prosecution
Patent Portfolio Management, Monetization, and Transactions: Due Diligence; Opinions and Counseling; Patent Mining and Mapping
Post-Grant Proceedings: IPR, PGR, and CBM

Stefan's Industries

Chemicals, Industrials, and Materials: Chemical
Life Sciences: Biotechnology; Pharmaceutical

Stefan O. Ochiana, Ph.D.

Et Cetera

Experience

News

Professional Activities

Admissions

Education

Languages

Stefan's Practices

Stefan's Industries

If you have European patents, you need to know about the Unified Patent Court (UPC).